HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

azd9684

inhibitor of carboxypeptidase U

Also Known As:

(3R)-2-((6-Aminopyridin-3-yl)methyl)-3-sulfanylbutanoic acid

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Butyrates: 2613
      - azd9684: 1
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Butyrates: 2613
      - azd9684: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - azd9684: 1

Experts

1.	Boisseau, William: 1 article (12/2020)
2.	Desilles, Jean-Philippe: 1 article (12/2020)
3.	Di Meglio, Lucas: 1 article (12/2020)
4.	Ducroux, Célina: 1 article (12/2020)
5.	Hendriks, Dirk: 1 article (12/2020)
6.	Jandrot-Perrus, Martine: 1 article (12/2020)
7.	Lambeir, Anne-Marie: 1 article (12/2020)
8.	Leenaerts, Dorien: 1 article (12/2020)
9.	Loyau, Stéphane: 1 article (12/2020)
10.	Mazighi, Mikael: 1 article (12/2020)

Related Diseases

1.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 12/01/2020 - "Rats were subjected to transient middle cerebral artery occlusion (tMCAO) and received recombinant tissue-type plasminogen activator (tPA), a specific CPU inhibitor (AZD9684), combination therapy of tPA and AZD9684, or saline for 1 hour using a randomized treatment regime. "
2.	Thrombosis (Thrombus) 12/01/2020 - "In addition, the effects of the selective CPU inhibitor AZD9684 on CPU kinetics, microvascular thrombosis (MT), and AIS outcome were evaluated. "
3.	Infarction (Infarctions) 12/01/2020 - "Selective inhibition of CPU with AZD9684 was able to reduce fibrin(ogen) deposition and brain edema, suggesting a reduction of MT but without a significant effect on final infarct volume."
4.	Brain Edema (Cerebral Edema) 12/01/2020 - "Selective inhibition of CPU with AZD9684 was able to reduce fibrin(ogen) deposition and brain edema, suggesting a reduction of MT but without a significant effect on final infarct volume."

Related Drugs and Biologics

1.	Tissue Plasminogen Activator (Alteplase)
2.	Fibrin
3.	estropipate (Ogen)

Related Therapies and Procedures

1.	Therapeutics